Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS)

Inclusion Criteria \_ALS-patients: * Age ≥18 years * Able to provide written informed consent prior to study participation * Body weight of ≥ 50 kg and a body mass index (BMI) between 19-30 kg/m2 * Vital signs measured after three minutes resting in the supine position must be within the following ranges: * oral body temperature: 35.0-37.5 °C * systolic blood pressure: 90-140 mm Hg * diastolic blood pressure: 50-90 mm Hg * pulse rate: 40-90 bpm * Clinically probable, probable laboratory supported, or definite ALS-diagnosis according to the revised version of the El Escorial World Federation of Neurology criteria (EEC) (46) * Disease duration ≤ 18 months since date of diagnosis * Slow vital capacity (sVC) ≥ 80 % of normal (best of three measurements) * Pre-study ALSFRS-R progression between disease onset and screening of -0.4 points/month or worse (calculated by ALSFRS-R score decline from 48 divided by months since symptom onset until screening) * Patient has to be on a stable dose of disease modifying treatments (Edaravone 60 mg i.v. on ten days/month, Riluzole 100 mg/day) nclusion Criteria \_Healthy controls * Age ≥ 18 years * Able to provide written informed consent prior to study participation * Body weight of ≥ 50 kg and a body mass index (BMI) between 19-30 kg/m2 * Vital signs measured after 3 minutes resting in the supine position must be within the following ranges: * oral body temperature: 35.0-37.5 °C * systolic blood pressure: 90-140 mm Hg * dia…